Skip to content

A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (REBUILD-SM trial)

A Randomised Clinical Trial of the effect of a digital Self-Management package on health-related quality of life for people with Interstitial Lung Disease (REBUILD-SM trial)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12623001133628
Enrollment
78
Registered
2023-11-02
Start date
2024-06-07
Completion date
2026-12-01
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The REBUILD-SM trial will evaluate the efficacy of a combined self-management package and smartphone application for people with interstitial lung disease (ILD). This intervention will be supported by phone calls from health professionals. Participants will be allocated to either the intervention or control group and take part in the 12-week intervention, with follow-up at 6 and 12 months. It is hoped that the intervention will improve health-related quality of life for people with ILD by helping them better manage their chronic condition.

Interventions

This study compares REBUILD-SM with standard care in people with interstitial lung disease (ILD). REBUILD-SM comprises a purpose-built smartphone app that allows subjects to enter and track health data over time and an integrated self-management website. Participants will enter their respiratory diagnosis, medications and side effects, weight, lung function test results, oxygen saturation level and supplemental oxygen usage into the smartphone app. They will also use the app to complete questi

This study compares REBUILD-SM with standard care in people with interstitial lung disease (ILD). REBUILD-SM comprises a purpose-built smartphone app that allows subjects to enter and track health data over time and an integrated self-management website. Participants will enter their respiratory diagnosis, medications and side effects, weight, lung function test results, oxygen saturation level and supplemental oxygen usage into the smartphone app. They will also use the app to complete questionnaires at specific timepoints. Participants will input most of this data at the beginning of the trial and then update it when it changes, for example, after obtaining a new lung function result, starting a new medication or getting a new side effect from an existing medication. Entering data into the app is expected to take around 30 minutes at the start of the trial, and about 20 minutes at 12, 26 and 52 weeks when completing the questionnaires. Updating data is expected to take about 5-10 minutes and will only happen when there is a change, for example, once per week, although it may not be this frequent. The app will not provide any recommendations on the health data participants enter - it is simply for recording purposes. To ensure data collection is as complete as possible, electronic reminders will be sent when questionnaires are not completed at the specified timepoints and will alert the study team if the participant fails to complete the questionnaires in response to the reminder. This will prompt a phone call from a member of the study team to encourage endpoint completion. App analytics will be used in the data analysis phase (after the trial is over) to understand how participants engaged with the app. Participants in the intervention group will be asked to log into and use the self-management website with support from the study team. The self-management website includes the following 13 modules: understanding treatment options for pulmonary fibrosis; managing co-existing medical conditions; managing medications and side effects; role and importance of pulmonary rehabilitation and regular physical activity; understanding and accessing clinical trials; role of oxygen therapy; managing shortness of breath; smoking cessation advice and support; managing fatigue; accessing community support; managing mood; how to communicate with others when living with pulmonary fibrosis. During the intervention period, participants will receive four phone calls from a health professional involved in the management of people with ILD to help them set health-related goals and identify appropriate modules from the website to help achieve these goals. These four phone calls are expected to take about 15-30 minutes each. Each module provides information regarding the topic and provides access to relevant websites, fact sheets, booklets, videos and webinars as well as other external resources. Participants will have direct access to these external resources from within the package through hyperlinks embedded in the title of each resource. Participants are expected to work through their selected modules at their own pace – there is no specific amount of time they are required to allocate to the intervention, and they can utilise as many or as few of the resources as they like. Adherence to the intervention will be monitored through the four phone calls and engagement with the content.

Sponsors

The University of Sydney
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Educational / counselling / training
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Physician confirmed diagnosis of interstitial lung disease (ILD) • Able to provide informed consent • Able to read written English or have someone reading for them in their preferred language • Able to speak English • Own a smartphone or tablet compatible with RE-BUILD App • Digital literacy to be able to download and use smartphone application • Have an email address • On stable treatment for ILD for 1 month (no changes to ILD medications within 1 month prior to recruitment)

Exclusion criteria

• Unable to communicate in English • Unable to consent due to cognitive impairment or other reason • Not on stable treatment for ILD (changes to ILD medications within the previous 1 month) • Currently participating in pulmonary rehabilitation • Death or transplant anticipated within the study period • Digital illiteracy preventing download and use of apps

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026